AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01379339
Drug: Cabazitaxel 15mg/m2
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
Trial: NCT01379339
Drug: Cabazitaxel 17.5mg/m2
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
Trial: NCT01379339
Drug: Cabazitaxel 20mg/m2
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
Trial: NCT02062749
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting dose of Oxaliplatin is 175 mg/m2 delivered by hyperthermic intraperitoneal chemotherapy over 90 minutes.
Trial: NCT02477215
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.
Trial: NCT02477215
Drug: Bendamustine (multiple dose levels)
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 70 mg/m\^2, 80 mg/m\^2, or 90 mg/m\^2 on days 1 and 2
Trial: NCT02477215
Drug: Bendamustine (MTD)
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 80 mg/m\^2 on days 1 and 2
Trial: NCT04052425
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Trial: NCT03705858
Drug: Ac-Lintuzumab
RxNorm normalized name: 225Ac-lintuzumab
DrugBank: Lintuzumab (DB14877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225Ac-lintuzumab will administered at 4 dose levels: 0.25, 0.5, 0.75 or 1 µCi/kg intravenously (IV) over 30 ± 10 minutes. The starting dose will be 0.5 µCi/kg. A dose of 0.25 µCi/kg will be studied only if 0.5 µCi/kg is determined to exceed the MTD. The lintuzumab dose will be adjusted to maintain a specific activity of 0.16 µCi/µg
Trial: NCT03793517
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 200mg.m-2.d-1 intervanously on days -12 and -11
Trial: NCT04143815
Drug: MBA-P01 (Botulinum toxin A)
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intramuscular injection, dose varies by groups
Trial: NCT03651375
Drug: Sequential chemotherapy - 3 courses of AI
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna), one before radiotherapy and two within the gap between radiotherapy and surgery.
Trial: NCT01525966
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01525966
Drug: paclitaxel albumin-stabilized nanoparticle formulation
RxNorm normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01731951
Drug: Imetelstat
RxNorm normalized name: Imetelstat
DrugBank: Imetelstat (DB14909)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.
Trial: NCT00006292
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01720901
Drug: Icotinib
RxNorm normalized name: icotinib
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib will be administered 250 mg one time by month, 3 times per day.
Trial: NCT01404104
Drug: Temsirolimus (pre surgery)
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus will be given to patients 12 weeks prior to surgery (with a one week off period right before the surgery date).
Trial: NCT01128699
Drug: Subconjunctival Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intraoperative Subconjunctival Avastin 1.25mg; single dose as an adjunct to 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
Trial: NCT02779842
Drug: Coppertone (BAY 987517)
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. formulation number SR15-39-Z12-002.
Trial: NCT01460979
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25mg weekly intravenous until progression
Trial: NCT02626962
Drug: ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2)
Trial: NCT02626962
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
Trial: NCT04678089
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Objective To observe the safety and efficacy of bortezomib related biomarkers. Including genes, metabolites, etc
Trial: NCT01065662
Drug: temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given on days 1, 8, 15 and 22 of each cycle
Trial: NCT01065662
Drug: cediranib
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally daily
Trial: NCT02256956
Drug: Amitriptyline
RxNorm normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg / day for 10 days
Trial: NCT02256956
Drug: Tolterodine
RxNorm normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo 1 mg / day for 10 days
Trial: NCT01967927
Drug: 18F-MISO
RxNorm normalized name: 18F-MISO
DrugBank: Fluoromisonidazole F-18 (DB14830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A radiolabeled imaging agent that has been used for investigating tumor hypoxia with positron emission tomography (PET).
Trial: NCT03950271
Drug: SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. Neoadjuvant chemotherapy： SHR-1210 (200mg, d1, q3w) + trastuzumab ( 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 weeks) + capecitabine (1000mg/m2 bid d2-15, q3w) + Oxaliplatin (130mg/m2, d2, q3w)；4cycle~2. postoperative adjuvant chemotherapy： Capecitabine (1000mg/m2 bid d1-14, q3w) + oxaliplatin (130mg/m2, d1, q3w)；The total number of chemotherapy cycles is 8 cycles.
Trial: NCT04256642
Drug: Intrathecal morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine at the time of spinal anesthesia
Trial: NCT03978949
Drug: Bacillus Licheniformis
RxNorm normalized name: Bacillus licheniformis
DrugBank: Bacillus licheniformis (DB19247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
Trial: NCT00505765
Drug: AL-108
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL-108, 5 mg/day- one spray in each nostril once per day
Trial: NCT00505765
Drug: AL-108
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
Trial: NCT05497570
Drug: Tenoxicam Injectable Product
RxNorm normalized name: tenoxicam Injectable Product
DrugBank: Tenoxicam (DB00469)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After arthrocentesis procedure, 2-ml injection of tenoxicam (Oksamen-L, Mustafa Nevzat İlaç Sanayi, Istanbul, Turkey) to the temporomandibular joint
Trial: NCT00683852
Drug: Aripiprazole 5mg
RxNorm normalized name: ARIPIPRAZOLE 5MG TAB
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet dose of aripiprazole will be 2 mg/day during the first phase (30 days) of the study, and 5 mg/day in the second phase (30 days)
Trial: NCT00683852
Drug: Aripiprazole 2mg
RxNorm normalized name: ARIPIPRAZOLE 2MG TAB
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study (30 days)
Trial: NCT01852565
Drug: Darapladib
RxNorm normalized name: Darapladib
DrugBank: Darapladib (DB06311)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated, free base (micronized) white round tablet, 160mg, Oral/repeat dose/10 days (Treatment Period 1), 14 days (Treatment Period 2)
Trial: NCT01852565
Drug: Diltiazem
RxNorm normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended release, Blue capsule imprinted with cardizem CD and 240mg on one end, 240 mg, Oral/repeat dose/17 days
Trial: NCT03852446
Drug: Indoximod HCL (F2) tablets
RxNorm normalized name: Indoximod
DrugBank: Indoximod (DB12827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The doses will be ascending per cohort from 600 mg to 2400 mg
Trial: NCT03852446
Drug: Indoximod base formulation
RxNorm normalized name: Indoximod
DrugBank: Indoximod (DB12827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of 1200 mg
Trial: NCT03852446
Drug: Indoximod HCL (F2) tablets
RxNorm normalized name: Indoximod
DrugBank: Indoximod (DB12827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of 1200 mg
Trial: NCT02985996
Drug: Truvada
RxNorm normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.
Trial: NCT02985996
Drug: Genvoya
RxNorm normalized name: Genvoya
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.
Trial: NCT00561795
Drug: pazopanib (GW786034)
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 800 mg orally once a day for 6 cycles
Trial: NCT00561795
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV over one hour every 3 weeks of 6 cycles
Trial: NCT00561795
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV 175 mg/m\^2 given over 3 hours on day one of a 21 day cycle for six cycles
Trial: NCT02427334
Drug: Dienogest
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
Trial: NCT01015170
Drug: bupropion HCl
RxNorm normalized name: bupropion HCl
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg BID for up to 8 weeks + counseling
Trial: NCT03210909
Drug: BMS-986231
RxNorm normalized name: BMS-986231
DrugBank: Cimlanod (DB14983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986231
Trial: NCT02433704
Drug: Cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
Trial: NCT01213121
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet/25-600mg per day/once a day/six weeks
Trial: NCT04501380
Drug: AEMCOLO (Rifamycin SV MMX)
RxNorm normalized name: Aemcolo
DrugBank: Rifamycin (DB11753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be issued a patient kit containing AEMCOLO (Rifamycin SV MMX) 194 mg tablets for the 1st or the 2nd treatment regimen in a random order.
Trial: NCT02116036
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01207414
Drug: iloperidone
RxNorm normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.
Trial: NCT01473888
Drug: T89(Dantonic)
RxNorm normalized name: santonin
DrugBank: Santonin (DB19377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, 225mg B.I.D.
Trial: NCT00653510
Drug: Actrapid (human insulin)
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On day one the patients will receive glucose and insulin in order to reach a blood sugar around 18 and 20 mmol/L and on day two the patients will receive glucose and insulin in order to have a blood sugar around 5 and 7 mmol/L. On both days amino acid, lipid and glucose metabolism will be assessed by means of whole body isotope dilution.
Trial: NCT00416910
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00416910
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005966
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04281095
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each
Trial: NCT03857854
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: treatment group
Trial: NCT03697252
Drug: Xanomeline and Trospium Chloride Capsules
RxNorm normalized name: trospium chloride / xanomeline Pill
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-34 unless the subject is experiencing adverse events from the xanomeline 100 mg/trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/trospium 20 mg depending on clinical response and tolerability. Dosing must not change after Visit 7 of the study (at 21 ± 2 days of dosing) and may be decreased for tolerability reasons no more than once during the study.
Trial: NCT03286114
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg IV every 21 days
Trial: NCT02322632
Drug: Paricalcitol Capsules, 4 mcg
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
Trial: NCT03980665
Drug: Arsenic Trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: a arsenic class of mineral, clinically approved for treating acute promyelocytic leukemia
Trial: NCT04532528
Drug: Dabigatran
RxNorm normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran
Trial: NCT03435250
Drug: AG-270
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-270, orally, once or twice daily, on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
Trial: NCT02369874
Drug: MEDI4736 + Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4736 + Tremelimumab combination therapy
Trial: NCT03435250
Drug: AG-270
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-270, orally, once or twice daily, for 1 week prior to the first dose of docetaxel. Thereafter, AG-270 continues to be given daily, on Days 1 through 21 of each 21-day cycle, until disease progression or unacceptable toxicity.
Trial: NCT03435250
Drug: AG-270
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-270, orally, once or twice daily for 1 week prior to the first doses of nab-paclitaxel and gemcitabine. Thereafter, AG-270 continues to be given daily on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
Trial: NCT03435250
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel, IV, once during each 21-day cycle, until disease progression or unacceptable toxicity.
Trial: NCT03435250
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
Trial: NCT03435250
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
Trial: NCT02415608
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given orally in 28-day cycles
Trial: NCT02241616
Drug: Entecavir+Fuzheng Huayu+TCM Granule
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects will be taking 1 Entecavir tablet per day, 4 Fuzheng Huayu tablets three times a day and specific Traditional Chinese Medicine granule for 48 weeks.
Trial: NCT00272584
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01499940
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.
Trial: NCT02080715
Drug: Tolcapone
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 x 100mg Tolcapone compared to placebo (randomized, double-blind, cross-over)
Trial: NCT00634933
Drug: TRU-015
RxNorm normalized name: TRU-015
DrugBank: TRU-015 (DB05580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).
Trial: NCT00634933
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).
Trial: NCT00634933
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)